Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Entyvio tops Humira in ulcerative colitis

Takeda’s Entyvio tops Humira in ulcerative colitis

The VARSITY study pitted anti-integrin antibody Entyvio (vedolizumab) against Humira (adalimumab) – an anti-TNF drug and the biggest-selling medicine in the world – in patients at the more severe end

Latest news

More from news
Approximately 8 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics